Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 12/20 | 0.59 |
| ▸ | ALB | P02768 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 19/20 | 0.54 |
| ▸ | CA2 | P00918 | 19/20 | 0.54 |
| ▸ | CA4 | P22748 | 12/20 | 0.54 |
| ▸ | CA12 | O43570 | 9/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 9/20 | 0.54 |
| ▸ | CA3 | P07451 | 7/20 | 0.54 |
| ▸ | CA6 | P23280 | 7/20 | 0.54 |
| ▸ | CA5A | P35218 | 7/20 | 0.54 |
| ▸ | CA7 | P43166 | 7/20 | 0.54 |
| ▸ | CA13 | Q8N1Q1 | 7/20 | 0.54 |
| ▸ | CA5B | Q9Y2D0 | 7/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19370519 | 0.94 | CA1 (0.61) | CA9ALBCA1CA2CA4 | |
| SCHEMBL19370528 | 0.89 | CA1 (0.55) | CA9ALBCA1CA2CA4 | |
| SCHEMBL19370525 | 0.82 | CA1 (0.54) | CA9ALBCA1CA2CA4 | |
| SCHEMBL20832191 | 0.79 | CA9 (0.51) | CA9ALBCA1CA2CA4 | |
| SCHEMBL19359112 | 0.79 | CA1 (0.83) | CA9CA1CA2CA4CA12 | |
| SCHEMBL18475601 | 0.78 | CA9 (0.49) | CA9ALBCA1CA2CA4 | |
| SCHEMBL26259415 | 0.76 | CA1 (0.54) | CA9ALBCA1CA2CA4 | |
| SCHEMBL19370529 | 0.74 | CA9 (0.40) | CA9ALBCA1CA2CA4 | |
| SCHEMBL14583956 | 0.73 | TLR2 (0.62) | — | |
| SCHEMBL19359108 | 0.73 | CA2 (0.97) | CA9CA1CA2CA4CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10857234-B2 | Carbonic anhydrase IX inhibitor conjugates and uses thereof | ENDOCYTE INC. (US) | 2020-12-08 | — | — | US | disclosed |
| US-20190083631-A1 | CARBONIC ANHYDRASE IX INHIBITOR CONJUGATES AND USES THEREOF | ENDOCYTE, INC. (US) | 2019-03-21 | — | — | US | disclosed |
| WO-2017161144-A1 | CARBONIC ANHYDRASE IX INHIBITOR CONJUGATES AND USES THEREOF | ENDOCYTE, INC. (US) | 2017-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10857234-B2 | Carbonic anhydrase IX inhibitor conjugates and uses thereof | CA9, CA13, CA4 | CA9 1/4885ALB 2799/4885CA1 8/4885 |
| US-20190083631-A1 | CARBONIC ANHYDRASE IX INHIBITOR CONJUGATES AND USES THEREOF | CA9, CA13, CA4 | CA9 1/4885ALB 2799/4885CA1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.